Bizarre Patents
A kissing shield comprised of a thin, flexible membrane and a frame or holder.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8080250 | Immunoconjugates with an intracellularly-cleavable linkage The present invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a therapeutic moiety, and further relates to processes for making an... | 12/20/2011 |
| 8043621 | Recombinant fusion protein and polynucleotide construct for immunotoxin production The present invention relates to a polynucleotide construct encoding a fusion protein consisting of a domain which binds the immunoglobulin Fc region, genetically fused to a truncated form of Pseudomonas exotoxin A (PE). In particular, the invention discloses... | 10/25/2011 |
| 8039000 | Nucleic acid and corresponding protein entitled 158P3D2 useful in treatment and detection of cancer A novel gene (designated 158P3D2) and its encoded protein, and variants thereof, are described wherein 158P3D2 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 158P3D2 provides a ... | 10/18/2011 |
| 7927597 | Methods to inhibit cell growth A novel gene 109P1D4 and its encoded protein, and variants thereof, are described wherein 109P1D4 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 109P1D4 provides a diagnostic, p... | 04/19/2011 |
| 7892554 | Internalizing ErbB2 antibodies This invention provides novel erbB2-binding internalizing antibodies. The antibodies, designated F5 and C1, specifically bind to c-erbB2 antigen and, upon binding, are readily internalized into the cell bearing the c-erbB2 marker. Chimeric molecules comprising the F... | 02/22/2011 |
| 7887810 | Clostridial toxin derivatives able to modify peripheral sensory afferent functions This invention describes a novel agent for the targeted control of a mammalian cell activity, in particular the agent is used to control the interaction of particular cell types with their external environment. The agent has applications as a pharmaceutical for the ... | 02/15/2011 |
| 7740853 | Fcepsilon-pe chimeric protein for targeted treatment of allergy responses a method for its production and pharmaceutical compositions containing the same The present invention generally relates to a new approach for the therapy of allergic responses, based on targeted elimination of cells expressing the FcεRI receptor by a chimeric cytotoxin Fc2′-3-PE40. A sequence encoding amino acids 301-43... | 06/22/2010 |
| 7704506 | Fcε-PE chimeric protein for targeted treatment of allergy responses a method for its production and pharmaceutical compositions containing the same The present invention generally relates to a new approach for the therapy of allergic responses, based on targeted elimination of cells expressing the FcεRI receptor by a chimeric cytotoxin FC2′-3-PE40. A sequence encoding amino acids 301-43... | 04/27/2010 |
| 7615225 | Methods for treating a subject having cancer by the administration of a conjugate between a variant staphylococcal entertoxin E superantigen and an antibody that binds to the 5T4 antigen The present invention relates to compositions and methods of use, wherein the composition comprises a conjugate of a bacterial superantigen and an antibody moiety. More particularly, the bacterial superantigen has been modified to decrease seroreactivity with retain... | 11/10/2009 |
| 7541034 | Recombinant antibodies and immunoconjugates targeted to CD-22 bearing cells and tumors Methods and compositions relating to recombinant anti-CD22 antibodies with high binding affinity, and immunoconjugates comprising the anti-CD22 antibody linked to a therapeutic agent such as a Pseudomonas exotoxin or a detectable label. The invention provides... | 06/02/2009 |
| 7517527 | Immunotoxin with in vivo T cell suppressant activity and methods of use Provided is a method of treating an autoimmune disease in an animal comprising administering to the animal an antibody-DT mutant immunotoxin which routes by the anti-CD3 pathway, or derivatives thereof, under conditions such that the autoimmune disease is treated. I... | 04/14/2009 |
| 7425328 | Tissue factor antibodies and uses thereof The present invention provides antibodies capable of binding to human tissue factor, which do not inhibit tissue factor mediated blood coagulation compared to a normal plasma control. Further described are methods of making and methods of using the antibodies of the... | 09/16/2008 |
| 7393531 | Cytotoxicity mediation of cells evidencing surface expression of MCSP This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more ... | 07/01/2008 |
| 7387772 | Chimeric, human and humanized anti-CSAP monoclonal antibodies The present invention provides humanized, chimeric and human anti-CSAp antibodies and anti-CSAp antibody fusion proteins that are useful for the treatment and diagnosis of various cancers, including colon cancer. ... | 06/17/2008 |
| 7378091 | Antibodies against carbonic anhydrase IX (CA IX) tumor antigen The present invention relates generally to the generation and characterization of anti-CA IX monoclonal antibodies. The invention further relates to the use of such anti-CA IX antibodies in the diagnosis and treatment of disorders associated with increased activity ... | 05/27/2008 |
| 7371723 | Therapeutic agents comprising pro-apoptotic proteins The present invention relates to targeted killing of a cell utilizing a chimeric polypeptide comprising a cell-specific targeting moiety and a signal transduction pathway factor. In a preferred embodiment, the signal transduction pathway factor is an apoptosis-induc... | 05/13/2008 |
| 7361343 | Cytotoxicity mediation of cells evidencing surface expression of CD63 This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more ... | 04/22/2008 |
| 7361342 | Cancerous disease modifying antibodies The present invention relates to a method for producing patient cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the produ... | 04/22/2008 |
| 7361336 | Methods of cancer therapy targeted against a cancer stem line Improved methods for treatment of cancer which involve the targeting of slow-growing, relatively mutationally-spared cancer stem line are provided. These methods are an improvement over previous cancer therapeutic methods because they provide for very early cancer t... | 04/22/2008 |
| 7358334 | B cell-targeted toxins for humoral immune response reduction and methods of use thereof Disclosed herein are compositions and methods for selectively inhibiting and/or killing a target sub-population of B cells. ... | 04/15/2008 |
| 7332567 | Fret protease assays for clostridial toxins The present invention provides clostridial toxin substrates useful in assaying for the protease activity of any clostridial toxin, including botulinum toxins of all serotypes as well as tetanus toxins. A clostridial toxin substrate of the invention contains a donor ... | 02/19/2008 |
| 7329542 | Probes for identifying cancer-specific antigens This invention relates to the diagnosis of cancer, and in particular to the identification and detection of cancer-specific antigens, the invention provides antibody probes and methods for using the probes for detection and purification of cancer-specific antigens, ... | 02/12/2008 |
| 7319139 | TAG-72 specific C2 domain deleted antibodies Methods, compositions and kits comprising dimeric antibodies for the treatment of neoplastic, autoimmune or other disorders are provided. The dimeric antibodies of the instant invention may comprise two antibody molecules (H4L4) having the same... | 01/15/2008 |
| 7314632 | exotoxin A-like chimeric immunogens This invention provides Pseudomonas exotoxin A-like chimeric immunogens that include a non-native epitope in the Ib domain of Pseudomonas exotoxin. Methods of eliciting an immune response using these immunogens also are provided. ... | 01/01/2008 |
| 7307154 | DNA encoding a novel RG1 polypeptide The present invention relates to novel human extracellular matrix polypeptides, designated RG1, polynucleotides encoding the polypeptides, methods for producing the polypeptides, expression vectors and genetically engineered host cells for expression of the polypept... | 12/11/2007 |
| 7288255 | Prevention of immunoreactivity by depleting or inhibiting antigen presenting cells The invention includes compositions and methods for depleting antigen presenting cells, or for impairing the biological function of antigen presenting cells, which compositions are useful for treatment of graft versus host disease and other immune diseases. ... | 10/30/2007 |
| 7285269 | Antibodies directed to tumor necrosis factor Antibodies directed to the antigen TNFα and uses of such antibodies. In particular, fully human monoclonal antibodies directed to the antigen TNFα. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, ... | 10/23/2007 |
| 7285631 | Human cDNAs and proteins and uses thereof The invention concerns GENSET polynucleotides and polypeptides. Such GENSET products may be used as reagents in forensic analyses, as chromosome markers, as tissue/cell/organelle-specific markers, in the production of expression vectors. In addition, they may be use... | 10/23/2007 |
| 7285635 | Modified proteins, designer toxins, and methods of making thereof The present invention concerns methods of reducing the antigenicity of a proteinaceous compound while maintaining the compounds biological activity, as well as proteinaceous compositions with biological activity but reduced antigenicity. These methods and compositio... | 10/23/2007 |
| 7282476 | Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer Disclosed herein are modified proaerolysin (PA) peptide. In some examples, the proteins include a prostate-specific protease cleavage site and can further include a prostate-tissue-specific binding domain which functionally replaces the native PA binding domain. In ... | 10/16/2007 |
| 7273722 | Neurotoxins with enhanced target specificity Modified neurotoxins that contain protease cleavage sites susceptible uniquely to proteases present in certain tissues are described. The toxins can be selectively activated by proteases in muscle or selectively inactivated by proteases in blood. ... | 09/25/2007 |
| 7264809 | Methods of inhibiting platelet activation and recruitment The present invention provides soluble CD39 polypeptides and compositions, and methods for inhibiting platelet activation and recruitment in a mammal comprising administering a soluble CD39 polypeptide. ... | 09/04/2007 |
| 7255866 | Botulinum toxin therapy for fibromyalgia Methods for treating fibromyalgia by administering a therapeutically effective amount of a botulinum toxin to a patient with fibromyalgia. ... | 08/14/2007 |
| 7247301 | Human monoclonal antibodies to epidermal growth factor receptor (EGFR) Isolated human monoclonal antibodies which specifically bind to human EGFR, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, ca... | 07/24/2007 |
| 7229626 | Botulinum toxin therapy for neuropsychiatric disorders Methods for treating psychiatric disorders include intracranial administration of a therapeutically effective amount of a neurotoxin, such as a botulinum toxin type A, to a human patient. ... | 06/12/2007 |
| 7226601 | Conjugate between a modified superantigen and a target-seeking compound and the use of the conjugate A method for the treatment of a disease in a mammal by administering a therapeutically effective amount of a conjugate comprising a biospecific affinity counterpart and a peptide, wherein the peptide contains an amino acid sequence that is derived from staphylococca... | 06/05/2007 |
| 7227002 | Human antibodies that bind human 17-A1/EpCAM tumor antigen The present invention provides an anti-human antibody or fragment thereof that is low or not immunogenic in humans. In particular, the antibodies or fragments are directed to human tumor antigens, preferably to the human tumor antigen 17-1A, also known as EpCAM, EGP... | 06/05/2007 |
| 7226596 | Compositions and methods for the treatment of tumors The invention concerns compositions and methods for the diagnosis and treatment of neoplastic cell growth and proliferation in mammals, including humans. The invention is based upon the identification of an ADAM8 gene that is amplified in the genome of tumor cells. ... | 06/05/2007 |
| 7223397 | Potentiation of anti-CD38-Immunotoxin cytotoxicity The present invention is directed to the use of agents that induce high levels of cell surface molecules to provide targets for immunotoxins directed against the same cell surface molecules. A specific example is given in which all-trans-retinoic acid (RA) is used t... | 05/29/2007 |
| 7208285 | Fret protease assays for botulinum serotype A/E toxins The present invention provides clostridial toxin substrates useful in assaying for the protease activity of any clostridial toxin, including botulinum toxins of all serotypes as well as tetanus toxins. A clostridial toxin substrate of the invention contains a donor ... | 04/24/2007 |
